Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Common Equity (2012 - 2026)

Kamada's (KMDA) quarterly Common Equity came in at $269.6 million in Q2 2026, up 3.69% on a YoY basis from $260.0 million in Q2 2025, and up 3.92% quarter-over-quarter from $259.4 million in Q1 2026.

Analysis

Kamada (KMDA) Common Equity (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Common Equity for 15 consecutive years, with $269.6 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Common Equity rose 3.69% year-over-year to $269.6 million; the trailing twelve-month figure through Jun 2026 stood at $269.6 million (up 3.69% YoY), and the FY2025 full-year result was $269.1 million, up 3.7% from the prior year.
  • Common Equity improved to $269.6 million in Q2 2026 per KMDA's latest filing, from $259.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $269.6 million in Q2 2026 and bottomed at $171574.0 in Q2 2022.
  • Historically, Common Equity has averaged $219.4 million across 5 years, with a median of $251.2 million in 2024.
  • The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 99.91% in 2022, then soared 102917.94% in 2023.
  • Over 5 years, Common Equity stood at $176.0 million in 2022, then surged by 38.63% to $244.0 million in 2023, then increased by 6.33% to $259.5 million in 2024, then rose by 3.7% to $269.1 million in 2025, then climbed by 0.18% to $269.6 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $269.6 million, $259.4 million, and $269.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 8.42 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 1.35 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 18.85 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 4.92 Bn
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn 269.56 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 269.56 Mn
Mar 31, 2026 259.39 Mn
Dec 31, 2025 269.07 Mn
Sep 30, 2025 265.23 Mn
Jun 30, 2025 259.95 Mn
Mar 31, 2025 251.96 Mn
Dec 31, 2024 259.46 Mn
Sep 30, 2024 255.27 Mn
Jun 30, 2024 251.15 Mn
Mar 31, 2024 251.15 Mn
Dec 31, 2023 244.02 Mn
Sep 30, 2023 238.39 Mn
Jun 30, 2023 176.75 Mn
Mar 31, 2023 174.81 Mn
Dec 31, 2022 176.02 Mn
Sep 30, 2022 172.55 Mn
Jun 30, 2022 171,574.00
Mar 31, 2022 175.15 Mn
Dec 31, 2021 176.82 Mn
Sep 30, 2021 181.61 Mn